Cargando…
Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs
Pt(IV) prodrugs remain one of the most promising alternatives to conventional Pt(II) therapy due to their versatility in axial ligand choice and delayed mode of action. Selective activation from an external source is especially attractive due to the opportunity to control the activity of an antitumo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739791/ https://www.ncbi.nlm.nih.gov/pubmed/36498837 http://dx.doi.org/10.3390/ijms232314511 |
_version_ | 1784847896031526912 |
---|---|
author | Spector, Daniil Pavlov, Kirill Beloglazkina, Elena Krasnovskaya, Olga |
author_facet | Spector, Daniil Pavlov, Kirill Beloglazkina, Elena Krasnovskaya, Olga |
author_sort | Spector, Daniil |
collection | PubMed |
description | Pt(IV) prodrugs remain one of the most promising alternatives to conventional Pt(II) therapy due to their versatility in axial ligand choice and delayed mode of action. Selective activation from an external source is especially attractive due to the opportunity to control the activity of an antitumor drug in space and time and avoid damage to normal tissues. In this review, we discuss recent advances in photoabsorber-mediated photocontrollable activation of Pt(IV) prodrugs. Two main approaches developed are the focus of the review. The first one is the photocatalytic strategy based on the flavin derivatives that are not covalently bound to the Pt(IV) substrate. The second one is the conjugation of photoactive molecules with the Pt(II) drug via axial position, yielding dual-action Pt(IV) molecules capable of the controllable release of Pt(II) cytotoxic agents. Thus, Pt(IV) prodrugs with a light-controlled mode of activation are non-toxic in the absence of light, but show high antiproliferative activity when irradiated. The susceptibility of Pt(IV) prodrugs to photoreduction, photoactivation mechanisms, and biological activity is considered in this review. |
format | Online Article Text |
id | pubmed-9739791 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97397912022-12-11 Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs Spector, Daniil Pavlov, Kirill Beloglazkina, Elena Krasnovskaya, Olga Int J Mol Sci Review Pt(IV) prodrugs remain one of the most promising alternatives to conventional Pt(II) therapy due to their versatility in axial ligand choice and delayed mode of action. Selective activation from an external source is especially attractive due to the opportunity to control the activity of an antitumor drug in space and time and avoid damage to normal tissues. In this review, we discuss recent advances in photoabsorber-mediated photocontrollable activation of Pt(IV) prodrugs. Two main approaches developed are the focus of the review. The first one is the photocatalytic strategy based on the flavin derivatives that are not covalently bound to the Pt(IV) substrate. The second one is the conjugation of photoactive molecules with the Pt(II) drug via axial position, yielding dual-action Pt(IV) molecules capable of the controllable release of Pt(II) cytotoxic agents. Thus, Pt(IV) prodrugs with a light-controlled mode of activation are non-toxic in the absence of light, but show high antiproliferative activity when irradiated. The susceptibility of Pt(IV) prodrugs to photoreduction, photoactivation mechanisms, and biological activity is considered in this review. MDPI 2022-11-22 /pmc/articles/PMC9739791/ /pubmed/36498837 http://dx.doi.org/10.3390/ijms232314511 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Spector, Daniil Pavlov, Kirill Beloglazkina, Elena Krasnovskaya, Olga Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs |
title | Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs |
title_full | Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs |
title_fullStr | Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs |
title_full_unstemmed | Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs |
title_short | Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs |
title_sort | recent advances in light-controlled activation of pt(iv) prodrugs |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739791/ https://www.ncbi.nlm.nih.gov/pubmed/36498837 http://dx.doi.org/10.3390/ijms232314511 |
work_keys_str_mv | AT spectordaniil recentadvancesinlightcontrolledactivationofptivprodrugs AT pavlovkirill recentadvancesinlightcontrolledactivationofptivprodrugs AT beloglazkinaelena recentadvancesinlightcontrolledactivationofptivprodrugs AT krasnovskayaolga recentadvancesinlightcontrolledactivationofptivprodrugs |